NCT04625699 2023-06-06Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentColumbia UniversityPhase 2 Withdrawn
NCT03319316 2022-01-10SOLUTIONEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Withdrawn